Drug Development

Area of Science:

• Neuroscience
• Neurology
• Gerontology

Background:

• Non-invasive 40Hz light and sound stimulation shows potential in reducing Alzheimer's disease (AD) pathology in mouse models.
• Previous studies suggest 40Hz stimulation may enhance behavioral performance in AD.
• This study investigates 40Hz stimulation as a disease-modifying therapy for AD.

Purpose of the Study:

• To assess the long-term effects of daily 40Hz light and sound stimulation in Alzheimer's patients.
• To evaluate the safety and efficacy of sustained 40Hz neural activity induction.
• To explore the therapeutic potential of sensory stimulation for Alzheimer's dementia.

Main Methods:

• A 30-month open-label extension of a placebo-controlled trial involving daily home use of a 40Hz light and sound device.
• Participants included individuals with probable mild Alzheimer's disease (late-onset n=3, early-onset n=2).
• Evaluations included longitudinal EEG for neural activity, MRI for brain structure, actigraphy for sleep, neuropsychiatric testing for cognition, and plasma pTau217 levels.

Main Results:

• Chronic 40Hz stimulation was safe and well-tolerated over 30 months.
• EEG confirmed sustained and effective induction of 40Hz neural activity.
• Brain atrophy was slowed compared to historical controls, with cognitive improvements noted in late-onset AD patients.
• One participant showed a 47% reduction in plasma pTau217 levels.

Conclusions:

• Daily 40Hz light and sound stimulation is safe for long-term use and effectively slows neurodegeneration in Alzheimer's disease.
• Induced neural activity via sensory stimulation at 40Hz presents a promising novel therapeutic approach for Alzheimer's dementia.
• The findings support the potential of non-invasive gamma frequency stimulation as a disease-modifying treatment.